Dr. William Makis, a Canadian physician with expertise in radiology, oncology, and immunology, has proposed experimental protocols for treating advanced cancers, including stage 4, with a focus on what he terms "turbo cancers"—aggressive cancers he associates with COVID-19 mRNA vaccines. His approach involves repurposed drugs like ivermectin, fenbendazole, and mebendazole, often combined with other interventions. While these protocols are not part of mainstream oncology and lack large-scale clinical trial validation, they are based on his interpretation of emerging studies, case reports, and anecdotal evidence.
For stage 4 cancer, Dr. Makis advocates a combination of high-dose ivermectin and fenbendazole as a primary strategy, particularly for aggressive cases. He suggests a daily ivermectin dose of 1 mg per kg of body weight, which for a 70 kg (154 lb) person would equate to 70 mg per day. For fenbendazole, he recommends starting at 444 mg daily, with the potential to increase to 888 mg (444 mg twice daily) or even 1000 mg daily for severe cases, taken 6 days on and 1 day off each week. This regimen is intended to run for at least 3 months. He also mentions mebendazole as an alternative or complementary option, though specific dosing for stage 4 cancer is less detailed in available sources, with suggestions of 1000 mg weekly in some contexts.
In addition to these drugs, Dr. Makis emphasizes supportive therapies to enhance efficacy and patient resilience. These include:
-
High-dose intravenous Vitamin C (e.g., 25-50 grams via IV infusions), which he believes boosts immune function and targets cancer cells.
-
Fasting (such as intermittent or prolonged fasting) to reset the immune system and stress cancer cells.
-
Ketogenic diet, which he argues starves cancer cells of glucose, their preferred fuel.
-
Supplements like milk thistle (silymarin) for liver and kidney protection, Vitamin E (800 IU or mg daily—exact units unclear), curcumin, and CBD oil for their purported anti-cancer properties.
Dr. Makis claims this multimodal approach can lead to significant responses, even in stage 4 cases deemed untreatable by conventional oncology, citing anecdotal "cancer-free" outcomes. He bases this on studies like a 2021 Stanford case series on fenbendazole for stage 4 cancers and a 2017 Mexican study on ivermectin’s effects on breast cancer stem cells, as well as a 2024 peer-reviewed paper he co-authored on the "Mitochondrial-Stem Cell Connection" protocol. However, these claims rely heavily on preclinical data, small case series, and patient testimonials rather than randomized controlled trials.
It’s worth noting that Dr. Makis’ protocols are experimental and controversial. Mainstream oncology does not endorse these treatments due to insufficient evidence of efficacy and safety in humans at these doses. Patients considering this approach should consult a healthcare provider, as these drugs—typically used for parasitic infections—may interact with standard treatments like chemotherapy or pose risks at high doses. Dr. Makis himself acknowledges the hypothetical nature of his recommendations, urging patients to arm themselves with knowledge outside conventional medical advice.